Eli Lilly and Company (LLY)
Novo Nordisk Vs Eli Lilly: Novo A Clear Winner
Novo Nordisk stands out as the best pharma stock, outperforming Eli Lilly in key areas. Novo's higher profitability, stronger cash flow, and much lower valuation make it a more attractive investment than Lilly. Novo's discount could become a premium, as investors seek to diversify away from US stocks.
Eli Lilly's Stock Fall Is An Opportunity
I am bullish on Eli Lilly, despite recent underperformance and Orforglipron's clinical results falling short of high expectations. Eli Lilly's robust R&D, strong pipeline, and leadership in diabetes, obesity, and oncology underpin its long-term growth prospects. Recent financial results exceeded expectations, with raised guidance and continued market share gains in weight loss therapies, supporting valuation upside.
Eli Lilly's New Drugs Beyond Mounjaro and Zepbound Boost Sales
Eli Lilly's growing lineup beyond Mounjaro and Zepbound, including Omvoh and Jaypirca, is set to fuel revenue growth through 2025.
Novo's Wegovy Beats Lilly's Zepbound for Heart Health, Study Finds. What It Means for Stocks.
The study adds to growing evidence suggesting that the heart-protective benefits seen with Wegovy are specific to semaglutide.
Novo Nordisk's Wegovy cuts heart risk by 57% versus rival Lilly weight-loss drug in study
Novo Nordisk said on Sunday its blockbuster weight-loss drug Wegovy cut the risk of heart attack, stroke or death by 57% versus Eli Lilly's rival medicines Mounjaro and Zepbound in a real-world comparison of overweight and obese patients with cardiovascular disease but not diabetes.
Eli Lilly advances weight loss pill towards regulatory submissions after successful trial
Eli Lilly and Co (NYSE:LLY) shares moved higher Tuesday after the company reported positive late-stage trial results for its experimental oral obesity and diabetes drug, orforglipron. The Phase 3 study, known as ATTAIN-2, tested orforglipron in adults with obesity or overweight who also have Type 2 diabetes.
Eli Lilly Stock Rises as Firm Plans to Ask for Weight-Loss Pill Approval
Eli Lilly (LLY) shares gained more than 4% soon after the opening bell Tuesday as results from a new study moved the drugmaker closer to applying for approval of its experimental weight-loss pill.
Lilly obesity-pill trial results find a warmer reception on Wall Street this time around
Pharmaceutical giant Eli Lilly said it will now move “with urgency” toward getting regulatory approval for orforglipron.
Eli Lilly Says New Pill Results in 10.5% Weight-Loss for Diabetes Patients
Lilly said it's moving “with urgency toward global regulatory submissions to potentially meet the needs of patients who are waiting.”
Eli Lilly's weight loss pill orforglipron clears its latest trial, paving way for approval
Eli Lilly on Tuesday said its daily obesity pill succeeded in another late-stage trial, helping patients with obesity and Type 2 diabetes lose weight and lower their blood sugar levels. The company now has the full clinical trial data required to start filing for approvals of the drug for chronic weight management with global regulators.
Eli Lilly's obesity pill remains a viable rival to Novo's oral Wegovy despite data that underwhelmed investors
Some analysts say Eli Lilly's daily obesity pill, if approved, could still be a viable competitor in the weight loss drug market despite late-stage trial data that disappointed investors. In the trial, orforglipron caused weight loss that missed Wall Street's expectations and came below what Novo Nordisk reported for its oral drug in a separate study.
The Best Stocks to Invest $50,000 in Right Now
Congratulations, you've got $50,000 in unexpected cash! Will you buy a new car?
